— Know what they know.
Not Investment Advice

BCAX NASDAQ

Bicara Therapeutics Inc. Common Stock
1W: +0.9% 1M: -11.8% 3M: +34.6% YTD: +27.2% 1Y: +38.6%
$21.68
+0.84 (+4.03%)
 
Weekly Expected Move ±5.8%
$18 $19 $20 $21 $23
NASDAQ · Healthcare · Biotechnology · Alpha Radar Sell · Power 37 · $1.2B mcap · 35M float · 1.64% daily turnover · Short 60% of daily vol

Balance Sheet Trends

Total Assets
$431M -24.3% ▼
3Y CAGR: +300.6%
Total Liabilities
$30M -61.8% ▼
3Y CAGR: +7.2%
Shareholders Equity
$401M -18.4% ▼
Cash & Investments
$415M -15.3% ▼
3Y CAGR: +363.8%
Total Debt
$2M +131.7% ▲
Net Debt
-$95M +80.6% ▲

Assets vs Liabilities & Equity

Year-over-Year Growth

View Full Balance Sheet
Line ItemFY2022FY2023FY2024FY2025
— Assets —
Cash$4M$230M$490M$97M
Short-Term Investments$0$0$0$318M
Cash & ST Investments$4M$230M$490M$415M
Net Receivables$0$0$0$0
Inventory$0$0$0$0
Other Current Assets$68K$100K$13M$7M
Total Current Assets$5M$231M$503M$422M
Property, Plant & Equip.$636K$815K$845K$2M
Goodwill & Intangibles$0$0$0$0
Long-Term Investments$0$0$0$0
Other Non-Current Assets$1M$2M$7M$7M
Total Non-Current Assets$2M$3M$67M$9M
Total Assets$7M$234M$569M$431M
— Liabilities —
Accounts Payable$5M$3M$5M$6M
Short-Term Debt$0$0$607K$1M
Deferred Revenue$0$0$0$0
Other Current Liabilities$0$0$10M$22M
Total Current Liabilities$24M$15M$18M$29M
Long-Term Debt$0$0$0$593K
Other Non-Current Liab.$85K$17K$0$0
Total Non-Current Liabilities$85K$389K$59M$593K
Total Liabilities$24M$15M$77M$30M
— Equity —
Common Stock$2K$2K$7K$0
Retained Earnings-$101M-$153M-$221M$0
Accumulated OCI$0-$0$0$0
Total Stockholders Equity-$17M$219M$492M$401M
Total Liabilities & Equity$7M$234M$569M$431M
— Key Metrics —
Total Debt$0$657K$738K$2M
Net Debt-$4M-$230M-$489M-$95M
Total Investments$0$0$0$318M

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms